首页> 外文期刊>Clinical and experimental medicine >Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients
【24h】

Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients

机译:基因表达分析显示MCM3在侵入性导管乳腺癌患者的预后是比KI67更好的标记

获取原文
获取原文并翻译 | 示例
           

摘要

Invasive ductal carcinoma (IDC) is the most common breast cancer. Our study used gene microarray data to select differentially expressed genes between normal and IDC mammary tissues. From these, we selected genes related to the proliferation of tumor cells and compared their prognostic value with known biomarker Ki67 for IDC. Analysis of publicly available Gene Expression Omnibus (GEO) data revealed 24 differentially expressed genes (DEGs) in normal and 31 DEGS in IDC tissues that were used for further analyses. Gene chip analysis software was used to identify DEGs. DEG profiles were confirmed using quantitative PCR (qPCR). DEG functions where shown to be related to cell proliferation. We confirmed MCM3 expression using immunohistochemical staining in 45 IDC patients. The relationship between MCM3 expression and survival was investigated using Kaplan-Meier survival curves and Cox proportional hazard regression models. A total of 1307 differentially expressed genes were identified between IDC and normal tissues, which were enriched in 32 Gene Ontology (GO) terms and 9 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. qPCR demonstrated that both COL1A1 and MCM3 were significantly up-regulated in IDC tissues, of which only MCM3 was related to cell proliferation. Ki67 is closely associated with the tumor grade, ER status, PR status and HER2 status, while MCM3 was shown to relate to tumor size, lymph node, and PR status. There was significant association between survival and MCM3, but not for Ki67. High MCM3 expression demonstrated statistically significant associations with poor prognosis in IDC patients. Findings from the gene microarray data analysis confirmed that MCM3 is associated with the response to cell proliferation. MCM3 represents a better proliferation marker than Ki67 making it a valuable prognostic tool that is independent of ER and HER2 status.
机译:侵入性导管癌(IDC)是最常见的乳腺癌。我们的研究使用基因微阵列数据在正常和IDC乳腺组织之间选择差异表达的基因。从这些中,我们选择与肿瘤细胞增殖相关的基因,并将其预后值与已知的生物标志物Ki67进行了IDC。分析公共基因表达综合征(Geo)数据在用于进一步分析的IDC组织中揭示了正常的24个差异表达的基因(DEG)和31℃。基因芯片分析软件用于识别DEG。使用定量PCR(QPCR)确认涂层型材。 DEG功能显示与细胞增殖有关。我们在45名IDC患者中使用免疫组织化学染色确认了MCM3表达。使用Kaplan-Meier生存曲线和Cox比例危险回归模型研究了MCM3表达和存活之间的关系。在IDC和正常组织之间鉴定了总共1307个差异表达基因,其富集为32个基因本体论(GO)术语和9个基因和基因组(Kegg)途径的京都百科全书。 QPCR证明,在IDC组织中,COL1A1和MCM3显着上调,其中MCM3与细胞增殖有关。 KI67与肿瘤级,ER状态,PR状态和HER2状态密切相关,而MCM3显示出涉及肿瘤大小,淋巴结和公关状态。生存与MCM3之间存在重大关联,但不适用于KI67。高MCM3表达在IDC患者中表现出统计学上的重要组织,其预后差。基因微阵列数据分析的发现证实MCM3与对细胞增殖的响应有关。 MCM3表示比KI67更好的增殖标记,使其成为一个有价值的预后工具,其独立于ER和HER2状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号